Research
Hormonal
Brain-specific overexpression of SIRT1 extends lifespan and delays aging phenotypes in mice, primarily through hypothalamic regulation of metabolic homeostasis and circadian rhythms.
Current research suggests that longevity benefits from SIRT1 are specific to brain regions (hypothalamus) and cannot be assumed from global activation. While activators like SRT1720 show promise in mice, human application requires targeted mechanisms, not just general supplementation.
GoodSupportsHIGH confidence
mice with brain-specific transgenic over-expression of SIRT1 (BRASTO) have also recently been shown to have an extended lifespan (Satoh et al., 2013), and the specific SIRT1 activator SRT1720 extends lifespan of mice even when these were fed a standard diet (Mitchell et al., 2014).
Why this rating
Based on multiple transgenic mouse models (BRASTO) and pharmacological activation (SRT1720) showing consistent lifespan extension.
Source
SIRT1 in the brain—connections with aging-associated disorders and lifespan
Fanny Ng · Frontiers in Cellular Neuroscience · 2015
DOI 10.3389/fncel.2015.00064
narrative_reviewCited 185×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- SIRT1 levels in the brain decline with age, leading to cognitive impairment and metabolic dysfunction, while maintaining or increasing SIRT1 activity preserves synaptic plasticity and memory.Good
- SIRT1 activation in the hypothalamus regulates energy metabolism and circadian rhythms, influencing susceptibility to diet-induced obesity and metabolic disorders.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →